These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16682709)

  • 1. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data.
    Armstrong PW; Chang WC; Wallentin L; Goldstein P; Granger CB; Bogaerts K; Danays T; Van de Werf F;
    CMAJ; 2006 May; 174(10):1421-6. PubMed ID: 16682709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.
    Wallentin L; Goldstein P; Armstrong PW; Granger CB; Adgey AA; Arntz HR; Bogaerts K; Danays T; Lindahl B; Mäkijärvi M; Verheugt F; Van de Werf F
    Circulation; 2003 Jul; 108(2):135-42. PubMed ID: 12847070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
    Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
    Lancet; 2001 Aug; 358(9282):605-13. PubMed ID: 11530146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
    Sinnaeve PR; Alexander JH; Bogaerts K; Belmans A; Wallentin L; Armstrong P; Adgey JA; Tendera M; Diaz R; Soares-Piegas L; Vahanian A; Granger CB; Van De Werf FJ
    Am Heart J; 2004 Jun; 147(6):993-8. PubMed ID: 15199346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.
    Kaul P; Armstrong PW; Cowper PA; Eisenstein EL; Granger CB; Van de Werf F; Mark DB
    Am Heart J; 2005 Apr; 149(4):637-44. PubMed ID: 15990746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose.
    Rubboli A; Gatti C; Spinolo L; Parollo R; Spitali G; Maresta A
    Minerva Cardioangiol; 2006 Feb; 54(1):131-7. PubMed ID: 16467747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial.
    Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Danchin N; White HD; Santopinto J; Bigonzi F; Hecquet C; Vittori L;
    J Am Coll Cardiol; 2003 Oct; 42(8):1348-56. PubMed ID: 14563573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
    Antman EM; Morrow DA; McCabe CH; Murphy SA; Ruda M; Sadowski Z; Budaj A; López-Sendón JL; Guneri S; Jiang F; White HD; Fox KA; Braunwald E;
    N Engl J Med; 2006 Apr; 354(14):1477-88. PubMed ID: 16537665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
    Curtis JP; Alexander JH; Huang Y; Wallentin L; Verheugt FW; Armstrong PW; Krumholz HM; Van de Werf F; Danays T; Cheeks M; Granger CB;
    Am J Cardiol; 2004 Aug; 94(3):279-83. PubMed ID: 15276088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction.
    Armstrong PW; Wagner G; Goodman SG; Van de Werf F; Granger C; Wallentin L; Fu Y;
    Eur Heart J; 2003 Aug; 24(16):1515-22. PubMed ID: 12919776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS.
    Sinnaeve PR; Huang Y; Bogaerts K; Vahanian A; Adgey J; Armstrong PW; Wallentin L; Van de Werf FJ; Granger CB;
    Am Heart J; 2006 Oct; 152(4):684.e1-9. PubMed ID: 16996833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Streptokinase and enoxaparin as an alternative to fibrin-specific lytic-based regimens: an ExTRACT-TIMI 25 analysis.
    Giraldez RR; Wiviott SD; Nicolau JC; Mohanavelu S; Morrow DA; Antman EM; Giugliano RP
    Drugs; 2009 Jul; 69(11):1433-43. PubMed ID: 19634922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
    Dubois CL; Belmans A; Granger CB; Armstrong PW; Wallentin L; Fioretti PM; López-Sendón JL; Verheugt FW; Meyer J; Van de Werf F;
    J Am Coll Cardiol; 2003 Oct; 42(7):1178-85. PubMed ID: 14522476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey.
    Welsh RC; Goldstein P; Adgey J; Verheugt F; Bestilny SA; Wallentin L; Van de Werf F; Armstrong PW;
    Eur J Emerg Med; 2004 Jun; 11(3):134-40. PubMed ID: 15167171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
    Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial.
    Blazing MA; de Lemos JA; White HD; Fox KA; Verheugt FW; Ardissino D; DiBattiste PM; Palmisano J; Bilheimer DW; Snapinn SM; Ramsey KE; Gardner LH; Hasselblad V; Pfeffer MA; Lewis EF; Braunwald E; Califf RM;
    JAMA; 2004 Jul; 292(1):55-64. PubMed ID: 15238591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial.
    Lavi S; Cantor WJ; Casanova A; Tan MK; Yan AT; Džavík V; Fitchett D; Cohen EA; Borgundvaag B; Heffernan M; Ducas J; Goodman SG
    Am Heart J; 2012 Feb; 163(2):176-81.e2. PubMed ID: 22305834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
    Dunn CJ; Goa KL
    Am J Cardiovasc Drugs; 2001; 1(1):51-66. PubMed ID: 14728052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unfractionated heparin-clopidogrel combination in ST-elevation myocardial infarction not receiving reperfusion therapy.
    Bugiardini R; Dorobantu M; Vasiljevic Z; Kedev S; Knežević B; Miličić D; Calmac L; Trninic D; Daullxhiu I; Cenko E; Ricci B; Puddu PE; Manfrini O; Koller A; Badimon L;
    Atherosclerosis; 2015 Jul; 241(1):151-6. PubMed ID: 25988359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.